{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:42:18Z","timestamp":1740159738397,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Systemic sclerosis (SSc) is a rare connective tissue disease associated with rapid evolving interstitial lung disease (SSc-ILD), driving its mortality. Specific biomarkers associated with the evolution of the lung disease are highly needed. We aimed to identify specific biomarkers of SSc-ILD to predict the evolution of the disease. Nucleosomes are stable DNA\/protein complexes that are shed into the blood stream making them ideal candidates for biomarkers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We studied circulating cell-free nucleosomes (cf-nucleosomes) in SSc patients, 31 with ILD (SSc-ILD) and 67 without ILD. We analyzed plasma levels for cf-nucleosomes and investigated whether global circulating nucleosome levels in association with or without other biomarkers of interest for systemic sclerosis or lung fibrosis (e.g., serum growth factors: IGFBP-1 and the MMP enzyme: MMP-9), could be suitable potential biomarkers for the correct identification of SSc-ILD disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found that H3.1 nucleosome levels were significantly higher in patients with SSc-ILD compared SSc patients without ILD (<jats:italic>p<\/jats:italic>&lt; 0.05) and levels of MMP-9 were significantly increased in patients with SSc-ILD compared to SSc patients without ILD (<jats:italic>p<\/jats:italic>&lt; 0.05). Conversely, IGFBP-1 was significantly reduced in patients with SSc-ILD compared to SSc without ILD (<jats:italic>p<\/jats:italic>&lt; 0.001). The combination of cf-nucleosomes H3.1 coupled to MMP-9 and IGFBP-1 increased the sensitivity for the differential detection of SSc-ILD. High levels of accuracy were reached with this combined model: its performances are strong with 68.4% of positive predictive value and 77.2% of negative predictive value for 90% of specificity. With our model, we identified a significant negative correlation with FVC % pred (<jats:italic>r<\/jats:italic>= \u22120.22) and TLC % pred (<jats:italic>r<\/jats:italic>= \u22120.31). The value of our model at T1 (baseline) has a predictive power over the Rodnan score at T2 (after 6-18\u2009months), showed by a significant linear regression with<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>= 19% (<jats:italic>p<\/jats:italic>= 0.013). We identified in the sole group of SSc-ILD patients a significant linear regression with a<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>= 54.4% with the variation of DLCO between T1 and T2 (<jats:italic>p<\/jats:italic>&lt; 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In our study, we identified a new blood-based model with nucleosomic biomarker in order to diagnose SSc-ILD in a SSc cohort. This model is correlated with TLC and FVC at baseline and predictive of the skin evolution and the DLCO. Further longitudinal exploration studies should be performed in order to evaluate the potential of such diagnostic and predictive model.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13148-020-00915-4","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T11:03:45Z","timestamp":1597662225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A new nucleosomic-based model to identify and diagnose SSc-ILD"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7800-1730","authenticated-orcid":false,"given":"Julien","family":"Guiot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique","family":"Henket","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9atrice","family":"Andre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marielle","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Hardat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makon-Sebastien","family":"Njock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Moermans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Malaise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Louis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"915_CR1","unstructured":"Bonhomme O, Andr\u00e9 B, Gester F, de Seny D, Moermans C, Struman I, et al. Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature. Rheumatology. 2019 [cited 2019 Aug 11];61(6 Pt 1):67\u20139. Available from: https:\/\/academic.oup.com\/rheumatology\/advance-article\/doi\/10.1093\/rheumatology\/kez230\/5530892."},{"key":"915_CR2","doi-asserted-by":"crossref","unstructured":"Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007 [cited 2020 Mar 2];66(7):940\u20134. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17329309.","DOI":"10.1136\/ard.2006.066068"},{"key":"915_CR3","doi-asserted-by":"crossref","unstructured":"Del Papa N, Pignataro F, Zaccara E, Maglione W, Minniti A. Autologous hematopoietic stem cell transplantation for treatment of systemic sclerosis. Front Immunol. 2018 [cited 2020 Mar 2];9:2390. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30386340.","DOI":"10.3389\/fimmu.2018.02390"},{"key":"915_CR4","doi-asserted-by":"crossref","unstructured":"Guiot J, Moermans C, Henket M, Corhay J-L, Louis R. Blood biomarkers in idiopathic pulmonary fibrosis. Lung. 2017;195(3).","DOI":"10.1007\/s00408-017-9993-5"},{"key":"915_CR5","doi-asserted-by":"crossref","unstructured":"Guiot J, Struman I, Chavez V, Henket M, Herzog M, Scoubeau K, et al. Altered epigenetic features in circulating nucleosomes in idiopathic pulmonary fibrosis. Clin Epigenetics. 2017;9(1).","DOI":"10.1186\/s13148-017-0383-x"},{"key":"915_CR6","doi-asserted-by":"crossref","unstructured":"Cappelli S, Guiducci S, Bellando Randone S, Matucci Cerinic M. Immunosuppression for interstitial lung disease in systemic sclerosis. Eur Respir Rev. 2013 [cited 2020 Mar 2];22(129). Available from: https:\/\/err.ersjournals.com\/content\/22\/129\/236.","DOI":"10.1183\/09059180.00001813"},{"key":"915_CR7","unstructured":"Holdenrieder S, Dharuman Y, Standop J, Trimpop N, Herzog M, Hettwer K, et al. Novel serum nucleosomics biomarkers for the detection of colorectal cancer. Anticancer Res. 2014 [cited 2016 Nov 20];34(5):2357\u201362. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24778043."},{"key":"915_CR8","doi-asserted-by":"crossref","unstructured":"Holdenrieder S, Nagel D, Schalhorn A, Heinemann V, Wilkowski R, von Pawel J, et al. Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci. 2008 [cited 2016 Nov 17];1137(1):180\u20139. Available from: http:\/\/doi.wiley.com\/10.1196\/annals.1448.012.","DOI":"10.1196\/annals.1448.012"},{"key":"915_CR9","doi-asserted-by":"crossref","unstructured":"Raschi E, Chighizola CB, Cesana L, Privitera D, Ingegnoli F, Mastaglio C, et al. Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts. Arthritis Res Ther. BioMed Central; 2018 [cited 2020 Mar 28];20(1):187. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30157947.","DOI":"10.1186\/s13075-018-1689-6"},{"key":"915_CR10","doi-asserted-by":"crossref","unstructured":"Tzouvelekis A, Kaminski N. Epigenetics in idiopathic pulmonary fibrosis. Biochem Cell Biol. 2015 [cited 2016 Nov 17];93(2):159\u201370. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25659821.","DOI":"10.1139\/bcb-2014-0126"},{"key":"915_CR11","doi-asserted-by":"crossref","unstructured":"Robinson CM, Watson CJ, Baugh JA. Epigenetics within the matrix: a neo-regulator of fibrotic disease. Epigenetics. 2012 [cited 2016 Nov 17];7(9):987\u201393. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22894907.","DOI":"10.4161\/epi.21567"},{"key":"915_CR12","doi-asserted-by":"crossref","unstructured":"Tsou P-S, Sawalha AH. Unfolding the pathogenesis of scleroderma through genomics and epigenomics. J Autoimmun. NIH Public Access; 2017 [cited 2020 Mar 28];83:73. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5573604\/.","DOI":"10.1016\/j.jaut.2017.05.004"},{"key":"915_CR13","doi-asserted-by":"crossref","unstructured":"Yoshizaki A, Taniguchi T, Saigusa R, Fukasawa T, Ebata S, Numajiri H, et al. Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells. Ann Rheum Dis. 2016 [cited 2020 Mar 26];75(10):1858\u201365. Available from: http:\/\/ard.bmj.com\/lookup\/doi\/10.1136\/annrheumdis-2015-207405.","DOI":"10.1136\/annrheumdis-2015-207405"},{"key":"915_CR14","doi-asserted-by":"crossref","unstructured":"Guiot J, Henket M, Corhay JL, Moermans C, Louis R. Sputum biomarkers in IPF: evidence for raised gene expression and protein level of IGFBP-2, IL-8 and MMP-7. PLoS One. Public Library of Science; 2017 [cited 2018 Dec 19];12(2):e0171344. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28178340.","DOI":"10.1371\/journal.pone.0171344"},{"key":"915_CR15","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Cano D, Ortego-Centeno N, Callejas JL, Fonollosa Pl\u00e1 V, R\u00edos-Fern\u00e1ndez R, Tolosa-Vilella C, et al. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. Rheumatol Int. 2018 [cited 2018 May 21];38(3):363\u201374. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29322341.","DOI":"10.1007\/s00296-017-3916-x"},{"key":"915_CR16","unstructured":"Gester F, Duysinx B, Von Frenckell C, Louis R, Guiot J. Pattern of biological changes in interstitial lung diseases. Rev Med Liege. 2019 [cited 2019 Feb 15];74(1):47\u201353. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30680974."},{"key":"915_CR17","doi-asserted-by":"crossref","unstructured":"Godinas L, Corhay J-L, Henket M, Guiot J, Louis R, Moermans C. Increased production of TGF-\u03b21 from sputum cells of COPD: relationship with airway obstruction. Cytokine. 2017;99.","DOI":"10.1016\/j.cyto.2017.06.018"},{"key":"915_CR18","doi-asserted-by":"crossref","unstructured":"Guiot J, Bondue B, Henket M, Corhay JL, Louis R. Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis. BMC Pulm Med. 2016 [cited 2017 Jun 25];16(1):86. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27215343.","DOI":"10.1186\/s12890-016-0249-6"},{"key":"915_CR19","doi-asserted-by":"crossref","unstructured":"Inoue Y, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S, et al. Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype. Chest. 2020 [cited 2020 Apr 19]; Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369220305699.","DOI":"10.1016\/j.chest.2020.03.037"},{"key":"915_CR20","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013 [cited 2018 May 21];72(11):1747\u201355. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24092682."},{"key":"915_CR21","doi-asserted-by":"crossref","unstructured":"Smith V, Scir\u00e8 CA, Talarico R, Airo P, Alexander T, Allanore Y, et al. Systemic sclerosis: state of the art on clinical practice guidelines. RMD open. BMJ Publishing Group; 2018 [cited 2020 Mar 28];4(Suppl 1):e000782. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30402270.","DOI":"10.1136\/rmdopen-2018-000788"},{"key":"915_CR22","doi-asserted-by":"crossref","unstructured":"Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012 [cited 2017 Jul 28];366(21):1968\u201377. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22607134.","DOI":"10.1056\/NEJMoa1113354"},{"key":"915_CR23","doi-asserted-by":"crossref","unstructured":"Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. NIH Public Access; 2017 [cited 2020 Mar 28];2(1):11\u20138. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28516167.","DOI":"10.5301\/jsrd.5000231"},{"key":"915_CR24","doi-asserted-by":"crossref","unstructured":"Bauden M, Pamart D, Ansari D, Herzog M, Eccleston M, Micallef J, et al. Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer. Clin Epigenetics BioMed Central; 2015 [cited 2017 Feb 23];7(1):106. Available from: http:\/\/www.clinicalepigeneticsjournal.com\/content\/7\/1\/106.","DOI":"10.1186\/s13148-015-0139-4"},{"key":"915_CR25","doi-asserted-by":"crossref","unstructured":"Olin AI, M\u00f6rgelin M, Truedsson L, Sturfelt G, Bengtsson AA. Pathogenic mechanisms in lupus nephritis: nucleosomes bind aberrant laminin \u03b21 with high affinity and colocalize in the electron-dense deposits. Arthritis Rheum. 2014 [cited 2016 Nov 17];66(2):397\u2013406. Available from: http:\/\/doi.wiley.com\/10.1002\/art.38250.","DOI":"10.1002\/art.38250"},{"key":"915_CR26","doi-asserted-by":"crossref","unstructured":"Guiot J, Struman I, Louis E, Louis R, Malaise M, Njock M-S. Exosomal miRNAs in lung diseases: from biologic function to therapeutic targets. J Clin Med. 2019 [cited 2020 Apr 19];8(9):1345. Available from: https:\/\/www.mdpi.com\/2077-0383\/8\/9\/1345.","DOI":"10.3390\/jcm8091345"},{"key":"915_CR27","doi-asserted-by":"crossref","unstructured":"Holdenrieder S, Stieber P, Bodenm\u00fcller H, Busch M, Fertig G, F\u00fcrst H, et al. Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer. 2001 [cited 2016 Nov 17];95(2):114\u201320. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11241322.","DOI":"10.1002\/1097-0215(20010320)95:2<114::AID-IJC1020>3.0.CO;2-Q"},{"key":"915_CR28","doi-asserted-by":"crossref","unstructured":"Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE. Pathogenesis of systemic sclerosis. Front Immunol. Frontiers; 2015 [cited 2020 Mar 26];6:272. Available from: http:\/\/journal.frontiersin.org\/Article\/10.3389\/fimmu.2015.00272\/abstract.","DOI":"10.3389\/fimmu.2015.00272"},{"key":"915_CR29","doi-asserted-by":"crossref","unstructured":"Kim W-U, Min S-Y, Cho M-L, Hong K-H, Shin Y-J, Park S-H, et al. Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis Res Ther. 2005 [cited 2019 Aug 11];7(1):R71. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15642145.","DOI":"10.1186\/ar1454"},{"key":"915_CR30","doi-asserted-by":"crossref","unstructured":"Andersen GN, Nilsson K, Pourazar J, Hackett T-L, Kazzam E, Blomberg A, et al. Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis. Respir Med. 2007 [cited 2020 Apr 19];101(10):2199\u2013206. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611107001849.","DOI":"10.1016\/j.rmed.2007.04.019"},{"key":"915_CR31","doi-asserted-by":"crossref","unstructured":"Harrison NK, Cambrey AD, Myers AR, Southcott AM, Black CM, du Bois RM, et al. Insulin\u2014like growth factor-1 is partially responsible for fibroblast proliferation induced by bronchoalveolar lavage fluid from patients with systemic sclerosis. Clin Sci. 1994 [cited 2020 Apr 19];86(2):141\u20138. Available from: https:\/\/portlandpress.com\/clinsci\/article\/86\/2\/141\/75986\/Insulinlike-Growth-Factor1-is-Partially.","DOI":"10.1042\/cs0860141"},{"issue":"12","key":"915_CR32","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.3899\/jrheum.080340","volume":"35","author":"Y Hamaguchi","year":"2008","unstructured":"Hamaguchi Y, Fujimoto M, Matsushita T, Hasegawa M, Takehara K, Sato S. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis. J Rheumatol. 2008;35(12):2363\u201371.","journal-title":"J Rheumatol"},{"key":"915_CR33","doi-asserted-by":"crossref","unstructured":"Duan C, Xu Q. Roles of insulin-like growth factor (IGF) binding proteins in regulating IGF actions. Gen Comp Endocrinol. 2005 [cited 2018 May 21];142(1\u20132):44\u201352. Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016648004003958.","DOI":"10.1016\/j.ygcen.2004.12.022"},{"key":"915_CR34","doi-asserted-by":"crossref","unstructured":"Molyneaux PL, Willis-Owen SAG, Cox MJ, James P, Cowman S, Loebinger M, et al. Host\u2013microbial interactions in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2017 [cited 2018 Nov 24];195(12):1640\u201350. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28085486.","DOI":"10.1164\/rccm.201607-1408OC"},{"key":"915_CR35","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3389\/fendo.2018.00499","volume":"9","author":"H Ding","year":"2018","unstructured":"Ding H, Wu T. Insulin-like growth factor binding proteins in autoimmune diseases. Front Endocrinol (Lausanne) Frontiers Media SA. 2018;9:499.","journal-title":"Front Endocrinol (Lausanne) Frontiers Media SA"},{"key":"915_CR36","doi-asserted-by":"crossref","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis\u2013associated interstitial lung disease. N Engl J Med. Massachusetts Medical Society; 2019 [cited 2019 Jul 6];380(26):2518\u201328. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1903076.","DOI":"10.1056\/NEJMoa1903076"},{"key":"915_CR37","doi-asserted-by":"crossref","unstructured":"Flaherty KR, Fell CD, Huggins JT, Nunes H, Sussman R, Valenzuela C, et al. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. Eur Respir J. European Respiratory Society; 2018 [cited 2020 Feb 21];52(2). Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29946005.","DOI":"10.1183\/13993003.00230-2018"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-020-00915-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-020-00915-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-020-00915-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T12:54:40Z","timestamp":1667825680000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-020-00915-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["915"],"URL":"https:\/\/doi.org\/10.1186\/s13148-020-00915-4","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"type":"print","value":"1868-7075"},{"type":"electronic","value":"1868-7083"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"21 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol was approved by the ethics committee \u201chospitalo-facultaire\u201d of Li\u00e8ge, and all subjects gave written consent before their enrolment (Belgian number: B707201422832; ref: 2014\/302).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MH and NH are employees of Belgian Volition SPRL.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}